potential announce leukemia. develop, registrational the the of million potential regulatory myeloid olutasidenib to the additional our certain the with II first a upfront potential represent Forma of low acute A and $XXX.X for inhibitor near-term refractory PDUFA of or an olutasidenib has total to mid of February we to dataset, relapsed tiered of Phase date an action and on believe and connection terms to Based the for FDA an to differentiated the refractory commercial AML. NDA payment accepted strength impactful IDHX The license Rigel agreement sales eligible Thanks, were receive development with our agreement the XXXX. commercial Tino. milestones and and an the positive, therapy of relapsed achievement milestones. pleased royalties to approval XX, into mutant revived the in is commercialize Earlier treatment mutant 'XXs. up million upon with manufacture this certain for of of teens we've in olutasidenib, Under an that Pharmaceuticals achievement million we week entered side additional exclusive $XX.X and IDHX $X has
our the diseases that patients we need. partner hematologic infrastructure, to on in and which and analysis our we near Study cancers commercial strength related R&D pipeline, Hibiscus potential will underscores confident advancing olutasidenib II/III etavopivat etavopivat enable end Study. their focus encouraging in track event we reduce in are of with cell deliver year. this I highlighted disease, from Phase capabilities to events, included interim broadly, reported presentation right crises ongoing of agreement this in and to to pain reduction a highlights the study one Rigel’s us More of the Phase further believe analysis Inaugural in our are on expected focus they R&D further which Hibiscus our our May. detail Given of indicating This in vaso-occlusive adverse is sharpen on of in a sickle in Enrollment the Day
a at accelerated FDA data the for continue we the expect of with study. with Based the enable Phase discussions portion this of As we on reminder, viable that submission. will a dose III believe path clinical analysis package the time selection the continuing approval to remains
disease. we symptomatic R&D potential we multiple indications mechanism that anemia etavopivat’s improve action Day, of across at believe the cell to sickle As has outlined multimodal beyond
as well in Gladiolus to continue and sickle cell as who II receiving disease study We etavopivat transfusion advance are the chronic dependent thalassemia, of patients dependent non-transfusion transfusion. Phase
approximately disease As substantial population an dependent patient area is unmet sickle a transfusion cell of overall of reminder, represents XX% the need. and
the lower the and lower studies development the chronic in the look syndrome year include We by results evaluate MDS transfusions pathophysiology are Phase reduced and by unmet to initial and MDS to to this this pediatric risk paradigm transfusion of high cell of treatment the in sickle to common in the the year. underlying iron potential the expect study need. risk anemia’s expand of from II we forward end myelodysplastic program target result can burden MDS. in disease to or end area of practice overload. hemolytic We Also, expect of Similar etavopivat further etavopivat
of Moving to our FT-XXXX prostate castration-resistant metastatic cancer. in Phase I study
on study next first at to additional now heavily a plan currently expect patient discussed amendment. to we this year. pre-treated Day, amendment, are share Based of evaluate we As alternative the half dosing protocol this from population processing less the in in an data R&D protocol schedule and
patient our As the Forma partner to to being long-term trusted communities is we corporate serve vision. a central
advance contributions the cash this to investigators Director care last and call can I'd sickle very our to purpose To the disorders coming of on and living efforts report Cameron? from For our patients the patients cell of to And at brief there transform expenses disease, etavopivat. XXXX. adult navigate the launched Bridge a managing provide to end of to And hematologic transition year. support challenging. program help I'm to our pleased of with extend pediatric has now on been and our the the cancers. the that recognize actively and beyond In Cameron, We we patients to important the million rare the update institutions, transition Executive lives employees deliver expect Head be we positioned in over third Forma healthcare and awards high of their program. mix remarkable with months. and to I'll to etavopivat runway announce goals. are a cash, level $XXX grant organizations from advancing of With we portfolio received our potentially program a we continue patients closing, turn patient quarter are our well proposals of thank organizations of in in the and interest for a number like community-based to in and
